TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: ESP vs ESP With PECS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Scheduled mitral valve replacement surgery~* obtained consent~Exclusion Criteria:~* allergy to oxycodone and local anesthetics~* depression, antidepressant drugs treatment~* epilepsy~* usage of painkiller before surgery~* addiction to alcohol or recreational drugs~* prolonged postoperative ventilation (over 2 hours)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- ESP (Type: EXPERIMENTAL): Before the induction of general anesthesia, Erector Spinae Plane (ESP) blockade will be done. Postoperative analgesia is provided with intravenous oxycodone. Patient-controlled analgesia pump (PCA) will be used for this purpose.
- PECS (Type: EXPERIMENTAL): Before the induction of general anesthesia, Erector Spinae Plane (ESP) block and Pectoral fascia type I and II will be done. Postoperative analgesia is provided with intravenous oxycodone. Patient-controlled analgesia pump (PCA) will be used for this purpose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase Ia/Ib Study of CS1001 in Subjects With Advanced Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. With advanced-stage or metastatic tumor (unresectable) and experienced progression since last anti-tumor treatment; standard therapy is not available or rejected.~2. ECOG performance status of 0 or 1.~3. Subjects must have at least one measurable lesion.~4. Patients with life expectancy ≥ 3 months.~5. Subject must have adequate organ function.~6. Fertile men and women of childbearing potential must agree to use an effective method of birth control from providing signed consent and for six months after last study drug administration.~Exclusion Criteria:~1. Known brain metastasis or other CNS metastasis that is either symptomatic or untreated.~2. Subjects with active autoimmune diseases or history of autoimmune diseases should be excluded.~3. Patients who have received immune checkpoint proteins/antibody/medicine (including PD-1, PD-L1, etc) for treatment.~4. Known history of HIV infection.~5. Hepatitis B surface antigen (HBsAg) and Hepatitis B core antibody (HBcAb) positive or Hepatitis C virus (HCV) antibody positive.~6. Patients who have serious hypersensitive reaction to monoclonal antibodies, and have history of uncontrolled allergic asthma.~7. Known history of alcoholism or drugs abuse.~For more information regarding trial participation, please contact at cstonera@cstonepharma.com

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- CS1001 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ocular Surface Syndrome Post-lasik, Outcomes of Treatment With Platelet Rich Plasma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult patients suffering from moderate to severe dry eye syndrome for 6 months or more after conventional treatments with artificial tears following LASIK.~* Tear break-up time (TBUT) between 4 and 9 seconds.~Exclusion Criteria:~* Ocular pathology needing topical treatments different than dry eye syndrome~* Trombocitopeny, associated pathologies to coagulation factors or any state of plaquets antiagregation (AAS and other AINES).~* Ocular tumours, corneal distrophies, history of ocular herpes.~* Pregnant or nursering women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Cinitapride Tablets in the Treatment of Mild to Moderate Functional Dyspepsia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion:~1. Aged between 18\~65 years, both males and females;~2. Patients with symptoms of mild to moderate functional dyspepsia;~3. Symptoms related to dyspepsia were developed 6 months ago and early satiety or/and discomfort after meal were developed in the past 3 months;~4. Gastrointestinal malignancy, peptic ulcer, liver, gallbladder and pancreas diseases were excluded through gastroscopy, B-ultrasonography and laboratory examination within 4 weeks prior to administration (endoscopy results considered to be clinically unrelated will not be excluded, such as small hiatal hernia and chronic nonatrophic pangastritis);~5. Patient has signed informed consent form.~Exclusion criteria~1. Patients with gastroesophageal reflux and/or irritable bowel syndrome;~2. Acid regurgitation more than once per week;~3. Previously received abdominal surgery (except appendectomy and herniorrhaphy);~4. A history of gastric or duodenal ulcer;~5. Patients with depression and anxiety neurosis;~6. Patients with arrhythmia;~7. QTc more than 0.5s;~8. Hepatic and renal insufficiency: AST or/and ALT equal to or above 1.5 times of the upper normal limit; Cr above the upper normal limit;~9. Pathological lactorrhea;~10. Patients with alcohol abuse (daily alcohol intake more than 40g), drug dependence or neuropsychiatric disorders that are difficult to control, as well as others who are not appropriate to participate in a drug trial;~11. Pregnant or lactating women;~12. Patients who require other therapy to change gastrointestinal mobility;~13. Patients who are participating or participated in other drug clinical trial within 3 months prior to entry;~14. Known to be allergic to cinitapride; Patients who are considered by investigators to be inappropriate to participate.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cystoinflation to Prevent Bladder Injury in Obstetrics and Gynaecology Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Part1:Inclusion Criteria:~* • Healthy pregnant women of any age~  * Two or more previous C-sections~ * Gestational age between 38-40 weeks (confirmed by dating scan)~ * Dense Adhesions of Tulandi scores four or more.~ * women who give informed consent to participate in the study~Exclusion Criteria~:• Patients with medical disorders~* Bladder injury before group assignment~* Placenta previa~* Subjects experiencing micturition problems (dysuria, frequency, urgency, urinary retention, incontinence) before the study.~Eligibility criteria of part 2\&3 will be provided after publication -

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Cystoinflation group (Type: EXPERIMENTAL): Bladder will be recognized by observing its gradual distension during bladder retro-fill with 300cc saline to perform adhesiolysis.
- Control group (Type: NO_INTERVENTION): Pelvic adhesiolysis will be performed without bladder retrofill.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of CJ-50300

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Healthy Korean male and female subjects between 20 and 28 years of age at the time of screening visit.~2. Willing to participate and have signed the informed consent form~3. In good general health, without clinically skin diseases history, physical examination or laboratory test results~4. Hematocrit \>33% for women; \>38% for men~5. White cell count 3,300-12,000/mm3~6. Total lymphocyte count \> 800 cells/mm3~Exclusion Criteria:~1. Diseases or conditions that cause immunodeficiency (For examples; HIV AIDS, leukemia, lymphoma, generalized malignancy, agammaglobulinemia, history of transplantation, therapy with alkylating agents, antimetabolites, radiation, or oral or parenteral corticosteroids).~2. In close physical contact (household or at work) with an individual who has the diseases or conditions that cause immunodeficiency~3. history or present of eczema or atopic dermatitis~4. Allergy or sensitivity to any known components of vaccine or other medicines~5. In close physical contact (household or at work) with an individual who has acute or chronic skin conditions such as dermatitis, exfoliative dermatitis~6. Subjects with inflammatory ophthalmic disease requiring steroid therapy~7. Subjects who are planning for blood donations~8. Autoimmune disease such as lupus erythematosus~9. Subjects who work in medical institution~10. Household contacts with women who are pregnant or breast-feeding~11. Female Subjects who are pregnant or breast-feeding and have positive result by serum pregnancy test or urine pregnancy test, or do not using approved contraceptives such as sterilization, contraceptive ring injectable, combined oral contraceptive pills and barrier contraceptive, combined hormone-based therapy, contraceptive cream, contraceptive jelly, diaphragm or condoms~12. Subjects household member \<1 year old or work with children \<1 year old~13. Subjects with a known history of Cardiac disease or have three or more of the following risk factors: hyperpiesia, obesity, hyperlipidemia, glucosuria, sclerosis, cerebral arteriosclerosis~14. Receipt of immunoglobulin and steroid within 14 days of vaccination~15. Receipt of investigational research agents within 120 days of vaccination~16. HBsAg seropositive~17. HCV antibody seropositive~18. HIV seropositive~19. Subjects having fever (oral temperature \> 38℃) or severe nutrition disorder~20. Blood donation within 12 weeks in advance screening visit~21. Subject who are not suitable to participate in study according to invesigator's judgement

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 28 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy Followed by Radiation Therapy in Patients With Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Microscopically proven small cell lung cancer~  * Diagnosis based on bronchial, mediastinal, pleural, lung, or lymph node biopsy, sputum cytology, or bronchial brushing or fine needle aspirate cytology~ * No pleural fluid cytology~* No prior therapy~PATIENT CHARACTERISTICS:~Age:~* Any age~Performance status:~* WHO 0-2~Hematopoietic:~* WBC more than 3,000~* ANC more than 1,500~* Platelets more than 100,000~Hepatic/Renal:~* Alkaline phosphatase, aminotransferase, sodium, and LDH normal or no more than 1 of them abnormal~* Creatinine or urea normal~* Creatinine clearance or GFR more than 65 mL/min~Other:~* No clinical evidence of infection~* No prior or concurrent malignancy that interferes with protocol treatments or comparisons~* No other condition that contraindicates treatment~* Willing and able to complete quality-of-life questionnaires~  * Hospital Anxiety and Depression Scale, Rotterdam Symptom Checklist, and EORTC questionnaires completed prior to randomization~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* See Disease Characteristics~Chemotherapy:~* See Disease Characteristics~Endocrine therapy:~* See Disease Characteristics~Radiotherapy:~* See Disease Characteristics~Surgery:~* See Disease Characteristics

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Aripiprazole in Patients With Bipolar I Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of bipolar I disorder, manic or mixed episode~Exclusion Criteria:~* First manic or mixed episode~* Allergic, intolerant, or unresponsive to lithium and valproate or to aripiprazole~* Participation in a previous clinical trial within the past month or ever participated in a trial with aripiprazole

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate MK1903 in Patients With Dyslipidemia (MK1903-004)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant is not on a statin or other lipid-modifying therapy~* Low or moderate risk participant~* Male participants, and female participants not of reproductive potential~Exclusion Criteria:~* Female participant of reproductive potential~* Participant is pregnant, breastfeeding, or expecting to conceive during the study~* Participant has history of cancer within 5 years of study (except certain types of skin and cervical cancer)~* Participant is a user of recreational or illicit drugs or has a recent history of drug and/or alcohol abuse~* Participant has donated or received blood within 8 weeks of study start or intends to give/receive blood during the study~* Participant consumes more than 3 alcoholic drinks per day or more than 14 alcoholic drinks per week~* Participant is currently experiencing menopausal hot flashes~* Participant currently engages in vigorous exercise or an aggressive diet regimen~* Participant is at high risk for heart conditions~* Participant has Type 1 or Type 2 diabetes mellitus~* Participant has poorly controlled cardiac arrhythmias~* Participant has a history of stroke or other hemorrhage~* Participant has poorly controlled high blood pressure~* Participant has a thyroid condition or other endocrine/metabolic disease that would affect serum lipids~* Participant has a disease of the kidney or liver~* Participant has an ulcer within 3 months of screening~* Participant is Human Immunodeficiency Virus (HIV) positive~* Participant is taking cyclical hormonal contraceptives or non-continuous hormone replacement therapy~* Participant is taking or has taken an Organic Anion Transporter (OAT1/3) inhibitor/substrate within 3 days of screening~* Participant has taken an anti-obesity medication within 3 months of screening~* Participant is taking coumarins~* Participant is taking Non-steroidal Anti-inflammatory Drugs (NSAIDs) (acetaminophen and Cyclooxygenase-2 (COX-2) inhibitors are allowed)~* Participant is taking more than 100 mg aspirin per day~* Participant is being treated with oral, intravenous, or injected corticosteroids or anabolic agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): MK1903
- 2 (Type: PLACEBO_COMPARATOR): Placebo to MK1903

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Majority fetal and sickle (FS or SF) hemoglobin pattern confirmed centrally by electrophoresis (screening may begin at 7 months of age)~Exclusion Criteria:~* Chronic transfusion therapy~* Cancer~* Less than 5th percentile (10th percentile for the pilot study) height, weight, or head circumference for age~* Severe developmental delay (e.g., cerebral palsy or other mental retardation, Grade III/IV intraventricular hemorrhage)~* Stroke with neurological deficit~* Surgical splenectomy~* Participating in other clinical intervention trials~* Probable or known diagnosis of Hemoglobin S-Hereditary Persistence of Fetal Hemoglobin~* Known hemoglobin S-beta plus thalassemia (hemoglobin A present)~* Any condition or chronic illness, which in the opinion of the principal investigator, makes participation unadvised or unsafe~* Inability or unwillingness to complete baseline (pre-enrollment) studies, including blood or urine specimen collection, liver-spleen scan, abdominal sonogram, neurological examination, neuropsychological testing, or transcranial Doppler ultrasound (interpretable study not required, but confirmed velocity greater than 200 cm/sec results in ineligibility)~* Previous or current treatment with hydroxyurea (HU) or another anti-sickling drug~* The following exclusion criteria are transient; patients can be re-evaluated for eligibility:~  1. Hemoglobin less than 6.0 gm/dL~ 2. Reticulocyte count less than 80,000/cu mm if hemoglobin is less than 9 gm/dL~ 3. Neutrophil count less than 2,000/cu mm~ 4. Platelet count less than 130,000/cu mm~ 5. Blood transfusion in the 2 months prior to study entry unless HbA is less than 10%~ 6. ALT greater than twice the upper limit of normal~ 7. Ferritin less than 10 ng/ml~ 8. Serum creatinine greater than twice the upper limit of normal for age~ 9. Bayley standardized mental score below 70

- Gender: ALL
- Minimum Age: 9 Months
- Maximum Age: 18 Months
- Healthy Volunteers: f

Study Arms:
- Hydroxyurea (Type: ACTIVE_COMPARATOR): Participants will receive hydroxyurea.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Predictive Executive Functioning Models Using Interactive Tangible-Graphical Interface Devices in Adults

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18+, males and females~* Individuals with ADHD~* Individuals without ADHD~* Depressive Disorders~* Anxiety Disorders~* High functioning Autism Spectrum Disorders~* Mood Disorders~Exclusion Criteria:~* Under the age of 18

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- ADHD group played Game (Type: EXPERIMENTAL): Groundskeeper, a Video Game Diagnostic Tool for ADHD is administer to probands with ADHD and age, gender matched controls without ADHD. The game was played on Sifteo cubes.
- Control group played game (Type: ACTIVE_COMPARATOR): Groundskeeper, a Video Game Diagnostic Tool for ADHD is administer to probands with ADHD and age, gender matched controls without ADHD. The game was played on Sifteo cubes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Safety and Effectiveness in Patients of All Age Groups Excluding Less Than 12 Months Old Infants With Diabetes Mellitus in Routine Clinical Practice in Korea

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria: - Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol) - The decision to initiate treatment with commercially available Tresiba® FlexTouch® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study - Male or Female, Age at least 12 months, at the time of signing informed consent with type 1 or type 2 diabetes mellitus and who is scheduled to start treatment with Tresiba® FlexTouch® based on the clinical judgment of their treating physician as specified in the Korean-Prescribing Information (KPI) Exclusion Criteria: - Previous participation in this study. Participation is defined as having given informed consent in this study - Patients who are or have previously treated with Tresiba® FlexTouch® - Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation. However, paediatric patients can be enrolled when the patient's primary caregiver (e.g. parents) or legally acceptable representatives (LAR) are capable of giving study specific signed informed consent. Any chronic disorder or severe disease which in the opinion of the investigator might jeopardise patient's safety or compliance with the protocol - Female who is pregnant, breast-feeding or intends to become pregnant and is of child-baring potential and not using adequate contraceptive methods (adequate contraceptive measures as required by local regulation or practice)

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Insulin degludec (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete